VP3.15 dihydrobromide

VP3.15 dihydrobromide 是一种高效、口服生物可利用且可渗透中枢神经系统的 PDE7-GSK3 双重抑制剂,对 PDE7 和 GSK3 的 IC50 值分别为 1.59 μM 和 0.88 μM,可提高细胞内 cAMP 水平、抑制免疫应答、增强髓鞘再生、限制 tau 蛋白过度磷酸化、减轻神经炎症与神经元损失、促进少突胶质前体细胞分化、改善体内髓鞘再生、抑制自身免疫性脑脊髓炎,并减轻生发基质-脑室内出血相关的脑损伤、脑萎缩、脑室扩大及认知障碍,可用于多发性硬化症和生发基质-脑室内出血的相关研究。
产品编号: MS-W60523 纯度: 98.0% CAS No.: 1281681-33-1 分子式: C20H24Br2N4Os 分子量: 528.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价
1g
询价
询价

产品描述

VP3.15 dihydrobromide 是一种高效、口服生物可利用且可渗透中枢神经系统的 PDE7-GSK3 双重抑制剂,对 PDE7 和 GSK3 的 IC50 值分别为 1.59 μM 和 0.88 μM,可提高细胞内 cAMP 水平、抑制免疫应答、增强髓鞘再生、限制 tau 蛋白过度磷酸化、减轻神经炎症与神经元损失、促进少突胶质前体细胞分化、改善体内髓鞘再生、抑制自身免疫性脑脊髓炎,并减轻生发基质-脑室内出血相关的脑损伤、脑萎缩、脑室扩大及认知障碍,可用于多发性硬化症和生发基质-脑室内出血的相关研究。

生物实验数据

生物活性 VP3.15 dihydrobromide is a potent, orally bioavailable, CNS-penetrant dual PDE7-GSK3 inhibitor with IC50 values of 1.59 μM for PDE7 and 0.88 μM for GSK3, which elevates intracellular cAMP levels, suppresses immune responses, enhances remyelination, limits tau hyperphosphorylation, alleviates neuroinflammation and neuronal loss, promotes oligodendrocyte precursor cell differentiation, improves remyelination in vivo, inhibits autoimmune encephalomyelitis, and attenuates germinal matrix-intraventricular hemorrhage-associated brain injury, brain atrophy, ventricular enlargement, and cognitive impairment, and can be used for research related to multiple sclerosis and germinal matrix-intraventricular hemorrhage.
IC50 & Target PDE7:1.59 μM, GSK-3:0.88 μM
体外研究
(In Vitro)

VP3.15 dihydrobromide 在无细胞生化分析中对 PDE7 的抑制作用 IC50 为 1.59 μM,对 GSK3 的抑制作用 IC50 为 0.88 μM。
VP3.15 dihydrobromide (1 μM; 5-10 DIV (体外培养天数)) 增强 P0 CD1 小鼠少突胶质前体细胞 (OPCs) 向 CNPase+-Olig2+ 和 MBP+-Olig2+ 成熟少突胶质细胞的分化,且不会改变少突胶质细胞的形态。
VP3.15 dihydrobromide (1 μM; 5 DIV) 可显著促进成人少突胶质前体细胞 (OPCs) 在 5 DIV 分化为 CNPase+ 成熟少突胶质细胞,且不会改变少突胶质细胞的形态。
VP3.15 dihydrobromide (5 μM; 1-3 DPL (损伤后天数)) 可显著增强 Lysophosphatidylcholines (LPC) (MS-X83911) 脱髓鞘的 P7 CD1 小鼠小脑切片在 3 DPL 时的髓鞘再生,但在 1 DPL 时未观察到任何作用。

Immunofluorescence

Cell Line: OPCs
Concentration: 1 μM
Incubation Time: 5, 7, 10 DIV
Result: Significantly increased the number of mature oligodendrocytes (identified as double-positive cells of CNPase+-Olig2+ and MBP+-Olig2+).
体内研究
(In Vivo)

VP3.15 dihydrobromide (10 mg/kg;腹腔注射;隔日 3 次 (1 周组);每周隔日给药,共 3 次 (3 周组)/2-3 doses) 可显著加速 Cuprizone (MS-G66252)、LPC 脱髓鞘模型中体内髓鞘再生进程,提高髓鞘再生纤维的髓鞘厚度。
VP3.15 dihydrobromide (10 mg/kg;每日;连续 7 天) 在脑室内出血小鼠中可改善认知障碍、减少出血和小胶质细胞负荷、限制脑萎缩、恢复神经元密度和髓鞘形成、促进神经发生,并使 p-GLS 水平恢复正常。

Animal Model: C57/BL6 (8-week-old male, demyelination induced by 5 weeks of ad libitum feeding with 0.2% Cuprizone mixed with milled chow/focal demyelination induced by stereotactic injection of 2 μl of 1% LPC into the corpus callosum)
Dosage: 10 mg/kg
Administration: i.p.; 3 alternate days (1-week group); 3 doses per week on alternate days (3-week group)/2 doses (14 dpi group); 3 doses (21 dpi group)
Result: Showed significantly higher eriochrome cyanine myelin staining and MBP fluorescence intensity in the corpus callosum one week after cuprizone withdrawal.
Had a significantly lower number of PDGFRα+ oligodendrocyte progenitor cells (OPCs) in the corpus callosum one week after cuprizone withdrawal.
Exhibited equivalent myelin staining (eriochrome cyanine and MBP) and OPC counts compared to vehicle controls three weeks after cuprizone withdrawal.
Showed no changes in microglial activation or astrocyte immunoreactivity compared to vehicle controls.
Significantly increased myelin sheath thickness (reduced G-ratio) compared to vehicle controls at both 14 and 21 dpi, with values approaching those of unlesioned control mice without evidence of hypermyelination.
Animal Model: CD1 (7-day-old at study initiation)
Dosage: 10 mg/kg
Administration: daily; 7 consecutive days (P7-P13)
Result: Improved learning in the Morris Water Maze (MWM) acquisition phase, restored time spent and number of entries in the target quadrant during 24-hour and 72-hour MWM retention tests, and normalized performance in the "where" paradigm of the New Object Discrimination test, compared to untreated GM-IVH mice.
Significantly reduced hemorrhage burden in the cortex at P14 and completely reversed cortical hemorrhage burden to control levels at P110; reduced hemorrhage burden in the hippocampus and striatum at P14, with a non-significant trend toward reduction at P110.
Reduced Iba1+ microglial burden to control levels in the cortex, hippocampus, and subventricular zone (SVZ) at P14; limited microglial burden increases in these regions at P110 compared to untreated GM-IVH mice.
Ameliorated reductions in brain weight at P14 and P110; significantly improved hemisection size at P110, normalized cortical size reductions at P14 and P110, and reduced ventricle enlargement at both time points compared to untreated GM-IVH mice.
Restored NeuN/DAPI ratios (neuronal density) in the cortex and SVZ at P14, and in the hippocampus at P110; reduced tau hyperphosphorylation (p-tau/total tau ratio) in the cortex at P110 to match control levels; restored myelin basic protein (MBP) levels in the cortex at P14.
Increased BrdU+ cell counts (proliferation), DCX+ area (neurogenesis), and BrdU/DCX ratio in the SVZ at P14; restored BrdU+ cell counts, DCX+ cell counts, and BrdU/DCX ratio in the dentate gyrus (DG) at P110, and normalized DCX+ cell counts in the DG at P14 compared to untreated GM-IVH mice.
Restored plasma gelsolin (p-GLS) levels to control values at P110.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 528.30
分子式 C20H24Br2N4Os
CAS No. 1281681-33-1

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.79 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 62.5 mg/mL (118.30 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8929 mL9.4643 mL18.9286 mL47.3216 mL
5 mM0.3786 mL1.8929 mL3.7857 mL9.4643 mL
10 mM0.1893 mL0.9464 mL1.8929 mL4.7322 mL
15 mM0.1262 mL0.6310 mL1.2619 mL3.1548 mL
20 mM0.0946 mL0.4732 mL0.9464 mL2.3661 mL
25 mM0.0757 mL0.3786 mL0.7571 mL1.8929 mL
30 mM0.0631 mL0.3155 mL0.6310 mL1.5774 mL
40 mM0.0473 mL0.2366 mL0.4732 mL1.1830 mL
50 mM0.0379 mL0.1893 mL0.3786 mL0.9464 mL
60 mM0.0315 mL0.1577 mL0.3155 mL0.7887 mL
80 mM0.0237 mL0.1183 mL0.2366 mL0.5915 mL
100 mM0.0189 mL0.0946 mL0.1893 mL0.4732 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础